The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. A visit to the chiropractor can provide many health benefits.

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

The market reacted swiftly, sending the price of Replimune shares crashing 77% lower on unusually high volume on July 22, 2025. “We're investigating whether Replimune may have misled investors about ...

Replimune Group (NASDAQ:REPL – Get Free Report) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports ...

Regencell Bioscience (RGC) stock surges 120% ending a 10-day losing streak as the company blames a potential short squeeze for share price volatility. Read more here.

UnitedHealth Group shares are sliding today following negative industry news from rival insurer Centene. Centene was forced to pull its full-year guidance due to troubling data. The company is ...

The recent robotaxi launch has altered the narrative surrounding the stock, and Tesla may reveal another event that could prove a positive catalyst for the company and the stock. Here's the lowdown.